Multiple tumour recurrence in oral, head and neck cancer: Characterising the patient journey

被引:17
|
作者
Wang, Weilan [1 ]
Adeoye, John [1 ]
Thomson, Peter [1 ]
Choi, Siu-Wai [1 ]
机构
[1] Univ Hong Kong, Hong Kong, Peoples R China
关键词
head and neck cancer; oral squamous cell carcinoma; tumour recurrence; SQUAMOUS-CELL CARCINOMA; CAVITY;
D O I
10.1111/jop.13182
中图分类号
R78 [口腔科学];
学科分类号
1003 ;
摘要
Background Oral squamous cell carcinoma (OSCC) is the 15th most common cause of cancer-related mortality worldwide and approximately one oral cancer-related death occurs for every two new diagnoses. Death-due-to-disease is usually ascribed to inoperable primary tumours, treatment complications, second primary tumours arising due to field cancerization, or locoregional recurrence and distant metastases. Methods A retrospective review of OSCC patients treated over a 19-year period, betweenOctober 1(st), 2000 and October 1(st), 2019. Patient demographic records were collected from consecutively treated adult patients with clinical subtypes corresponding to ICD-10 C00-C06, C09 and C10 were retrieved from the database. Patients who had suffered three or more recurrences after diagnosis of the primary tumour are defined as multiple-recurrent patients. Results A total of 467 OSCC patients were treated during the study period. One hundred and fifty-five patients developed recurrent OSCC, amongst which 22 were designated as multiple cases. The time between initial OSCC diagnosis and first tumour recurrence varied from 3 to 276 months. Nine of the 22 multiple patients (41%) were diagnosed with buccal mucosal SCC as the primary tumour, which is significantly higher than the average prevalence (or 4.4, 95% CI (1.8, 10.8), p < 0.001) for buccal tumours within the cohort. All patients were treated initially by surgical tumour excision. There were no demonstrable differences in adjuvant chemo-radiotherapy regimes in any of the study groups. Conclusion Multiple OSCC development may occur either synchronously or metachronously during the course of oral cancer disease and poses an important management problem in contemporary oncology practice.
引用
收藏
页码:979 / 984
页数:6
相关论文
共 50 条
  • [41] METABOLIC TUMOR VOLUME PREDICTS FOR RECURRENCE AND DEATH IN HEAD-AND-NECK CANCER
    La, Trang H.
    Filion, Edith J.
    Turnbull, Brit B.
    Chu, Jackie N.
    Lee, Percy
    Nguyen, Khoa
    Maxim, Peter
    Quon, Andy
    Graves, Edward E.
    Loo, Billy W., Jr.
    Le, Quynh-Thu
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2009, 74 (05): : 1335 - 1341
  • [42] Recurrence patterns after a decreased dose of 40 Gy to the elective treated neck in head and neck cancer
    Nevens, Daan
    Duprez, Frederic
    Daisne, Jean-Francois
    Schatteman, Julie
    Van der Vorst, Aline
    De Neve, Wilfried
    Nuyts, Sandra
    RADIOTHERAPY AND ONCOLOGY, 2017, 123 (03) : 419 - 423
  • [43] Pretreatment serum xanthophyll concentrations as predictors of head and neck cancer recurrence and survival
    Arthur, Anna E.
    Bellile, Emily L.
    Rozek, Laura S.
    Peterson, Karen E.
    Ren, Jianwei
    Harris, Ethan
    Mueller, Christie
    Jolly, Shruti
    Peterson, Lisa A.
    Wolf, Gregory T.
    Djuric, Zora
    HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, 2016, 38 : E1591 - E1597
  • [44] Telltale tumor infiltrating lymphocytes (TIL) in oral, head & neck cancer
    Lei, Yu
    Xie, Yuying
    Tan, Yee Sun
    Prince, Mark E.
    Moyer, Jeffrey S.
    Nor, Jacques
    Wolf, Gregory T.
    ORAL ONCOLOGY, 2016, 61 : 159 - 165
  • [45] Integrative care of the patient with head and neck cancer
    Nguyen, Chau T.
    Taw, Malcolm B.
    Wang, Marilene B.
    LARYNGOSCOPE INVESTIGATIVE OTOLARYNGOLOGY, 2018, 3 (05): : 364 - 371
  • [46] Improving head and neck cancer therapies by immunomodulation of the tumour microenvironment
    Ruffin, Ayana T.
    Li, Housaiyin
    Vujanovic, Lazar
    Zandberg, Dan P.
    Ferris, Robert L.
    Bruno, Tullia C.
    NATURE REVIEWS CANCER, 2023, 23 (03) : 173 - 188
  • [47] Radiologic Evaluation of the Head and Neck Cancer Patient
    Guenette, Jeffrey P.
    HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2021, 35 (05) : 863 - 873
  • [48] Impact of oral hygiene on head and neck cancer risk in a Chinese population
    Kawakita, Daisuke
    Lee, Yuan-Chin Amy
    Li, Qian
    Chen, Yuji
    Chen, Chien-Jen
    Hsu, Wan-Lun
    Lou, Pei-Jen
    Zhu, Cairong
    Pan, Jian
    Shen, Hongbing
    Ma, Hongxia
    Cai, Lin
    He, Baochang
    Wang, Yu
    Zhou, Xiaoyan
    Ji, Qinghai
    Zhou, Baosen
    Wu, Wei
    Ma, Jie
    Boffetta, Paolo
    Zhang, Zuo-Feng
    Dai, Min
    Hashibe, Mia
    HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, 2017, 39 (12): : 2549 - 2557
  • [49] Synthetic Lethality and PARP-Inhibitors in Oral and Head & Neck Cancer
    Forster, Martin
    Mendes, Ruheena
    Fedele, Stefano
    CURRENT PHARMACEUTICAL DESIGN, 2012, 18 (34) : 5431 - 5441
  • [50] Fear of recurrence following head and neck cancer in the outpatient clinic
    Rogers, S. N.
    Scott, B.
    Lowe, D.
    Ozakinci, G.
    Humphris, G. M.
    EUROPEAN ARCHIVES OF OTO-RHINO-LARYNGOLOGY, 2010, 267 (12) : 1943 - 1949